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Sensitive determination of 4-O-methylhonokiol in rabbit plasma
by high performance liquid chromatography and application to
its pharmacokinetic investigation
Ming-Yue Li, Yu-Hai Thng', Xia Liu, Hai-Yan Ui, Xi-Yan Shi
Institute of Analytical Science, Xi'an. ] iaotong University, Xi'an 710061, China.
Abstract: A novel high performance liquid chromatographic method was developed for the determination of 4-0-
methylhonokiol in rabbit plasma and was applied to its pharmacokinetic investigation. Plasma samples were treated by
one-fold volume of methanol and .acetonitrile to remove the interference proteins. A reverse phase column of SHIM-
PACK VP-ODS (150 mrn x 4. 6 mrn. 5.0 /lm) was used to separate 4-o-methylhonokiol in the plasma samples. The
detection limit of 4-o-methylhonokiol was 0.2 /lgiL and the linear range was 0.012 - 1. 536 mglL. The good extraction
recoveries were obtained for the spiked samples (84.7%. 89.3% and 87.7% for low. middle and high concentrations of
added standards, respectively). The relative standard deviation of intra-day and inter-day precisions was in the range
from 0.6% to 13.5%. The pharmacokinetic study of 4-o-methylhonokiol was made and the results from the plasma-
concentration curve of 4-o-methylhonokiol showed a two-apartment open model. This work developed a sensitive. stable
and rapid HPLC method for the determination of 4-o-methylhonokiol and the developed method has been successfully
applied to a pharmacokinetic study of 4-o-methylhonokiol.
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1 Introduction
Cortex Magnoliae Officinalis 0. e. Magnolia Bark), a tra-
ditional Chinese medicine (TCM), is the dried bark of the
trunk or root of Magnolia officinalis Rehd. etWils. or
Magnolia officinalis Rehd. etWils. vaT. biloba Rehd.
etWils., which belongs to the Magnoliaceae family. It has
been frequently used as an important ingredient in many
traditional prescriptions [1,2] and some concentrated com-
posite herbal preparations that contain Cortex Magnoliae
Officinalis in their prescriptions are widely used in oriental
countries because it can alleviate gastric and abdominal dis-
tension and other digestive discomforts, reduce the symp-
tom of cough and asthma due to the accumulation of
phlegm in the lung. and treat syndromes caused by emo-
tional distress, digestive disturbance, and emotional turmoil
[1]. Its antibacterial properties have been recognized and
may be responsible for its ability to alleviate digestive dis-
comforts due to some intestinal bacterial infections [2].
Several compounds were identified as the bioactive ingredi-
ents of Cortex Magnoliae Officinalis, including honokiol,
magnolol and 4-0-methylhonokiol (Figure 1). Previous re-
ports have shown that honokiol and magnolol have a broad
range of physiological activities such as anti-inflammatory
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[3], anti-oxidant [4], anti-tumor [5], anti- bacteria [6],
anti-arrhythmia [7], and anti-platelet [8]. The total con-
tent of honokiol and magnolol is an important parameter
for evaluating the quality of Cortex Magnoliae Officinalis.
Pharmacopoeia of P. R. China requires the total content of
honokiol and magnolol in Cortex Magnoliae Officinalis to
be no less than 2.0% [1]. As another bioactive ingredient,
the content of 4-0-methylhonokiol is within the range of
1. 0% - 2. 5% in Cortex Magnoliae Officinalis. The litera-
ture showed that 4-0-methylhonokiol could be developed as
an anti- inflammatory drug [9-11]. Previous study showed
that 4-0-methylhonokiol (l mglear) suppressed TPA-in-
duced ear edema, which was accompanied by the suppres-
sion on nuclear factor (NF)-ICB. inducible nitric oxide syn-
thase (iNOS) and cyclooxygenase 2 (COX-2) expression,
and was equivalent to the indomethacin (0. 5 mglear). Mo-
reover, no significant toxicity during a 28-day oral treat-
ment (l mglkg) was observed. Currently, there have been
reports about the determination of magnolol and honokiol
with the concentration of the drugs measured in vivo by
high-performance liquid chromatography (HPLC) at home
[12, 13]. However, no reports are found for the determina-
tion of 4-0-methylhonokiol and its pharmacokinetic study.
This work was designed to develop a novel method for the
determination of 4-0-methylhonokiol and its pharrnacoki-
netic study in rabbit'plasma by HPLC.
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Figure 1 Chemical structure of 4-O-methylhonokiol
2 Experimental
2.1 Otemicals and reagents
Methanol and acetonitrile were of HPLC grade and pur-
chased from Fisher Scientific (Springfield, NJ); Silica gel
G (00-200 mesh) was supplied by Qingdao Haiyang Chemi-
cal Co., Ltd. (China); Cortex Magnoliae Officinalis was
purchased from Xi'an Medical Company (China) and iden-
tified by Professor Guang-De Yang (Department of Phar-
macognosy, Xi'an Jiaotong University, Xi'an, China).
2.2 Instruments and experiment conditions
The LC analyses were accomplished using an LC-10Avp
(Shimadzu, Japan) HPLC system consisting of an LC-
10ATvp secondary pump system, a DGU-12A on-line
degasser, a crQ-10ASvp thermostatted column compart-
ment, and an SPD-MlOAvp diode array detector. CLASS-
VP software was used to control the LC components and to
process ultraviolet data. A reverse phase column of SHIM-
PACK VP-ODS (150 mm x 4.6 mm, 5.0 /-lm) was used.
The mobile phase consisted of methanol and water (85 : 15,
v/v). A flow-rate of 0.8 mVmin provided a retention time
of 6.6 min for 4-Q-methylhonokiol, whereas the runtime
was 13. 0 min for the chromatographic analysis of plasma
samples. Chromatograms were recorded at 294 nm using the
variable wavelength detector.
2.3 Preparation of 4-o-methylhonokiol standard from Mag-
noliae Officinalis
The bark of Magnoliae Officinalis was dried in the shade at
room temperature and stored in a dark, cold room until
use. The air-dried bark of Magnoliae Officinalis (150 g)
was cut into pieces and extracted twice with four-fold of
90% (viv) ethanol and water mixture for 4 hand 2 h respec-
tively. The filtered solution was concentrated under reduced
pressure and 2% NaOH solution was added to obtain the
extraction consisting of honokiol, magnolol and 4-Q-meth-
ylhonokiol. The contents of the three compounds in the
extraction were measured as 25.3%, 48.5% and 15.9%.
After filtering through the 400-mesh filter cloth, 2.0 M
hydrochloric acid was added to the resulting mixture to
adjust pH value of 1 - 2. Then, the stage extraction was
done using n-butanol, ethyl acetate and petroleum ether
through ethyl acetate layer. The suspension was dissolved in
chloroform and eluted with chloroform. The front layer
was evaporated to dryness, and the residue was separated
on silica gel using chloroform as the elute solvent to obtain
a crude fraction that included 4-Q-methylhonokiol. This
fraction was repeatedly purified by silica gel chromatogra-
phy using n-hexane and ethyl acetate as the solvents to ob-
tain 4-Q-methylhonokiol standard. Its content was meas-
ured as 95%. 4-Q-methylhonokiol was identified by J H-
NMR (400 MHz, COCb): a mglL: 3.35 (2H, d, aryl-
ca-), 3.44 (2H, d, aryl-Ca-), 3.90 (3H, s, -OMe) ,
5.05-5.20 (4H, m, 2 x -C=Ca), 5.94-6.07 (2H, m,
2 x -CH=C), 6.91 (lH, d, Ar-H), 6.98 (lH, d, Ar-H),
7.05-7.08 (2H, m, ArH), 7.24-7.31 (2H, m, ArH).
And 4-Q-methylhonokiol was identified by 13C_NMR (400
MHz, CDCb): a mglL: 34. 2( C-?), 39.3 (C-T), 55.5
(OMe) , 110.9 (C-3'), 115.4 (C-4'), 115.5 (C-9), 115.7
(C-9'), 127.8 (c-l'), 127.8 (C-6), 128.7 (C-3), 129.0
(C-1), 129.7 (C-5), 130.1 (C-6'), 130.4 (C-2), 132.11
(C-5'), 136.4 (C-8), 137.7 (C-8'), 151. 8 (C-2'), 157.0
(C-4). All the results were in agreement with previously
published data [14,15]. 4-Q-methylhonokiol was found to
exhibit a potent anti-inflammatory effect in different ex-
perimental models [16].
2.4 Preparation of the plasma samples
The fresh blood was collected from the heart of rabbit and
centrifuged at 4000 rpm for 10 min. 0.5 mL of plasma was
mixed with 0.5 mL methanol and 0.5 mL acetonitrile to
precipitate protein. The solution was vortex-mixed for 2
min and centrifuged for 10 min at 4000 rpm. An aliquot of
1. O' mL supernatant was oven dried at 40 ·C under the
stream of Nz • The residue was dissolved in mobile phase
consisting of 0.5 mL methanol-water (85 : 15, v/v) and
vortex-mixed for 1. 0 min. Twenty microlitres of the resul-
ting mixture was injected into HPLC system.
2.5 Preparation of standards and quality control samples
Stock solution of 1.0 mglmL 4-Q-methylhonokiol in meth-
anol was prepared in volumetric flasks. Calibration stand-
ard solution of 12.0 mglL 4-Q-methylhonokiol was pre-
pared by dilution and stored at 4 ·C. The working solutions
of calibration were prepared by diluting the standard solu-
tion with blank plasma to get the concentration of 0.012,
0.024,0.048,0.096,0.192,0.384,0.768 and l.536mglL.
The preparation of quality control (QC) samples with the
concentration of 0.02, O. 17 and 1. 20 mglL was the same
as the calibration standards.
2.6 Method validation
2.6.1 Selectivity
Selectivity was studied by comparing chromatograms of six
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different batches of blank plasma obtained from six subjects
with those of corresponding standard plasma samples spiked
with 4-O-methylhonokiol and plasma sample after oral
administration of the extracts.
2.6.2 Calibration and detection limits
The feasibility of the method was verified by plotting cali-
bration curves. The concentrations of the unknown samples
were determined using the equation of linear regression
obtained from the calibration curves. Limit of detection
(LOD) and limit of quantification (LOQ) for 4-O-methyl-
honokiol were determined at the signal-to-noise ratios(SlN)
of 3 and 10, respectively.
2.6.3 Precision and accuracy
Intra-day accuracy and precision (each n =5) were evalua-
ted by analysis of QC samples at different time within one
day. Inter-day accuracy and precision (each n = 6) were
determined by repeated analyses of QC samples twice per
day at three concentration levels over three consecutive
days. The concentration of each sample was determined
using calibration standards prepared on the same day.
Accuracy of the method was determined by the relative
standard deviation (CY).
2.6.4 Extraction recovery and matrix effect
The extraction recovery of 4-O-methylhonokiol was deter-
mined by comparing the peak areas obtained from blank
plasma samples spiked with the known amount of the ana-
lytes before extraction with those from post-extraction
blank plasma samples spiked at corresponding concentra-
tions. In order to evaluate the matrix effect on the ioniza-
tion of the analyte, 4-O-methylhonokiol of three different
concentration levels was added to the extract of 1. 0 mL of
blank plasma, evaporated and reconstituted with 0.25 mL
of mobile phase. According to the guidance of USFDA
[17 ], this procedure was repeated for five replicates at
three concentrations of 0.02, 0.17 and 1. 20 mg/L. The
corresponding peak areas (A) were compared with those of
4-O-methylhonokiol standard solutions evaporated directly
and reconstituted with the same mobile phase (B). The ra-
tio (NB x 100%) was used to evaluate the matrix effect.
'The matrix effect of the internal standard was also evalua-
ted by the same method.
2.6.5 Stability
Stability experiments were performed to evaluate the ana-
lyte stability in the stock solutions and in the plasma sam-
ples under different conditions, simulating the same condi-
tions which would occur during the study of sample analy-
sis. The long-term stability was evaluated by injecting the
QC plasma samples kept at low temperature ( - 70 ·C) for
60 d. The short-term stability of 4-O-methylhonokiol was
assessed by analyzing the QC plasma samples kept at ambi-
ent temperature (30·C) for 24 h prior to be processed, ana-
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lyzed and compared with the nominal values. In order to
estimate the stability of 4-O-methylhonokiol in the prepared
sample, five aliquots of QC samples at low, mid and high
concentration were kept in an auto-sampler maintained at
4 ·C for about 4 h in the prepared samples.
2.7 Application in phannacokinetic study
New Zealand healthy rabbits (2.0 - 2.4 kg) were obtained
from the Animal Center of )(j'an Jiaot~ng University. The
rabbits were kept in standard animal holding room at a
temperature of (23 ± 2)"C and a relative humidity of (60 ±
10)%. Water and food were allowed ad libitum. The ani-
mals were acclimatized to the facilities for 7 days and then
fasted with free access to water for 12 h prior to each
experiment. The ethics of animal experiments were in
accordance with the approval of the Department of Health
Guidelines in Care and Use of Animals.
The rabbits were given 4-O-methylhonokiol (single oral
dose of 0.6 mg/kg). Heparinized heart blood samples of
2.0 mL were collected just prior to dosing and then at 15
min, 35 min, 1 h, 2 h, 5 h, 6 h, 7 h, 8 hand 24 h after
administration. All the plasma samples were immediately
separated by centrifugation at 4000 rpm for 10 min, then
transferred into suitably labeled tubes and stored at - 20 ·C
for further use. Plasma drug concentration-time curves of
4-O-methylhonokiol were plotted by DAS 2.0 software.
2.8 Data analysis
The Microsoft Excel Program Drug and Statistics 2.0 (T. C.
M. Shanghai, China) were employed to process and calcu-
late the pharmacokinetic parameters. The parameters of the
area under curve (AUC) , the maximum plasma concentra-
tion (Colax) and the corresponding time (t max ), and the
half-life of absorption (t 112.) were used to decrypt the
pharmacokinetic properties of 4-O-methylhonokiol. Statis-
tical analysis of the biological data was performed by the
Student's t-test. All results are expressed as arithmetic
mean ± standard deviation (CY).
3 Results and discussion
3.1 Optimization of chromatographic separation
The selection of mobile phase components was critical to
the separation of 4-O-methylhonokiol. In the experiment,
different ratios (10 : 90, 15 : 85, 30 : 70, 50 : 50 and 70 :
30, v/v) of water/methanol were used as mobile phases to
optimize the separation effect. The ratio of 15 : 85 of wa-
ter/methanol was selected as the mobile phase in view of
retention time and peak shape of drug. In this work, am-
monium formate was employed to improve the resolution.
It was found that a mixture of 10 - 30 mM ammonium for-
mate buffer-water/methanol could preferably improve peak
shape and was finally not adopted as the mobile phase.
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Thble 1 Calibration curve details for the analysis of 4-o-methylhono-
kiol in rabbit plasma
a Relative bias = measured value - prepared value x 100
prepared value
.CV(coefficient of variation) = SD x 100
mean
3.2.4 Extraction recovery and matrix effect
The extraction recoveries of 4-O-methylhonokiol from
rabbit phisma were (84.7 ± 4. 9)%, (89.3 ± 2.9)%, and
(87.7 ± 4. 8)% at concentration levels of 0.02, 0.17 and
1.20 mg/L, respectively. In terms of matrix effect, all the
ratios (AlB x 100%) were between 99. 1% and 101. 3%,
which means no matrix effect for 4-O-methylhonokiol in
this method.
intra-day and inter-day precision and accuracy of the meth-
od. The results are presented in Table 2. The intra-day preci-
sion for low, mid and high QC levels of 4-O-methylhonokiol
was 11.8%, 1.2% and 0.6%, respectively, and that of inter-
day analysis was 13.5%,3.1% and 1.3%, respectively, with
an accuracy (RE) within -7.4% to 8.6%. The accuracy de-
viation values were within 12% of the nominal values. The
precision determined at each concentration level did not ex-
ceed 15% of the CY, revealing good precision and accuracy
for the method.
0.012 0.024 0.048 0.096 0.192 0.384 0.768 1.536
Concentfdlion of standard (mglL)
0.015 0.028 0.055 0.108 0.198 0.395 0.758 1.514
0.013 0.027 0.049 0.109 0.210 0.401 0.745 1.557
O.~ o.~ 0.5 O.~ O.~ o.e o.m 1.~
0.013 0.037 0.043 0.121 0.187 0.404 0.735 1.541
0.014 0.011 0.069 0.094 0.173 0.392 0.745 1.536
0.017 0.010 0.057 0.120 0.191 0.404 0.771 1.560
0.014 0.024 0.055 0.107 0.193 0.400 0.750 1.540
0.002 0.011 0.009 0.012 0.012 0.005 0.012 0.017
16.667 0.000 14.583 11.458 0.521 4.167 - 2.344 0.391
14.286 45.833 16.364 11.215 6.218 1.250 1.600 1.104
Calibration curves
FlISl
Second
Third
Fourth
Fifth
Sixth
Mean
SD
AcCUfdCY (relative bias" , %)
Precision (CVb )
3.2.5 Stability
Table 3 summarizes the results of the freeze-thaw stability.
long-term stability, short-term stability, and post-prepara-
tive stability of 4-O-methylhonokiol in rabbit plasma at
three QC levels. It was found that the concentrations of 4-
O-methylhonokiol at three QC levels had no obvious chan-
ges after six freeze-thaw cycles. The solutions were also sta-
ble at room temperature for 24 h, at 4 'C for 4 h, at - 70
'C for 60 days. These results demonstrated a good stability
of 4-O-methylhonokiol over all steps of the determination.
3.3 Application in phannacokinetic study
The present method was applied to the pharmacokinetic in-
vestigation of 4-O-methylhonokiol after administering single
oral dose of 0.6 mg/kg. Mean plasma drug concentration-
time curve of 4-O-methylhonokiol is shown in Figure 3,
and the calculating parameters are listed in Table 4. The
results indicated that the plasma profile of 4-O-methyl-
honokiol was a two-compartment open model.
A
40
::J
« 0
E
0 I ~
0.0 2.5 5.0 7.5 10.0 12.5
Time (min)
B
50
::J
« 25
E l
.......0
0.0 2.5 5.0 7.5 10.0 12.5
Time (min)
The regression equation of the curves and the correlation
coefficients (r) were calculated as Y =76820X + 60805 (Y
is the peak area ratio of 4-O-methylhonokiol, and X is the
plasma concentration of 4-O-methylhonokiol) and r =
0.9994 using weighted least squares linear regression (the
weighing factor was 1/C). Six calibration curves were line-
ar within the concentration range of 0.012 - 1.536 mg/L.
The CY of 4-O-methylhonokiol at each level varied from
1.1% to 45.8%. And the relative bias of 4-O-methylhono-
kiol from the theoretical value varied from - 2.3% to
16.7%. As a result, the calibration curves exhibited good
linearity within the experimental range. And the above
provided an adequate fit to the data (Table 1). The LOD
and LOQ of 4-O-methylhbnokiol were 0.2 fLg/L and 1 fLg/L.
3.2.3 Pncision and accuracy
The data from QC samples were calculated to estimate the
3.2. 2 Calibration and detection limits
Figure 2 Representative chromatograms of plasma samples. A, blank
plasma samples; B, plasmas sample after oral administration of 4-0-
methylhonokiol.
3. 2 Method validation
Selectivity was assessed by comparing the chromatograms of
six different batches of blank plasma with those of the cor-
responding spiked plasma. As shown in Figure 2, no inter-
ference from endogenous substance was observed at the
retention time of 4-0- methylhonokiol.
3.2.1 Selectivity
.. Phann Anal http://www.j-pharm-ana1.com
112 Ming-Yue Li, et al.
1llbIe 2 The inter-day and intra-day precision and accuracy of the method for determination of 4-O-methylhonokiol
Nominal
concentration
(mglL)
0.020
0.170
1.380
Intra-day Inter-day
Detected concentration Mean accuracy CV Detected concentration Mean accuracy CV
(mean ± SO, mglL) (%) (%) (mean ± SO. mglL) (%) (%)
0.020 ± 0.002 1.221 11. 780 0.018± 0.002 -11.485 13.463
0.169±0.OO2 -0.688 1.182 0.16S±0.OOS -3.226 3.146
1.36S±0.009 -1.085 0.628 1. 346 ± 0.018 - 2.498 1.309
4 Conclusion
Figure 3 Concentration versus time for 4-O-methylhonokiol in rabbit
plasma.
Thble 4 Pharmacokinetic parameters of 4-O-methylhonokiol after
oral administration of 4-O-methylhonokiol (0.6 mglkg) (n = 6)
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A sensitive. selective and rapid HPLC method for the de-
termination of 4-0-methylhonokiol in rabbit. plasma was
developed. And this method had the properties of reducing
ion suppression and offering superior sensitivity with an
LOQ of 0.001 mglL. satisfactory selectivity and short run
time of 13. 0 min. The proposed method has been success-
fully applied to a pharmacokinetic study of 4-0-methyl-
honokiol.
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